Galderma Group AG (FRA:PY3)
Germany · Delayed Price · Currency is EUR | Market Cap | 43.19B +21.1% |
| Revenue (ttm) | 5.18B +26.3% |
| Net Income | 755.38M +128.3% |
| EPS | 3.20 +129.8% |
| Shares Out | n/a |
| PE Ratio | 57.18 |
| Forward PE | 36.26 |
| Dividend | 0.38 (0.21%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 20 |
| Open | 179.00 |
| Previous Close | 182.00 |
| Day's Range | 179.00 - 184.00 |
| 52-Week Range | 138.00 - 202.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 23, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19... [Read more]
Financial Performance
In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.
Financial numbers in USD Financial StatementsNews
Galderma Reports Sustained Nemolizumab Benefits In Children With Atopic Dermatitis
(RTTNews) - Thursday, Galderma Group AG (GDERF) reported new Phase 2 data showing sustained improvements in itch, sleep disturbance, and quality of life through Week 52 with nemolizumab in children ag...
Galderma Group AG (GALDY) Acquires ZO Skin Health Inc. for $1.5 Billion to Expand U.S. ...
Galderma Group AG (GALDY) Acquires ZO Skin Health Inc. for $1.5 Billion to Expand U.S. Skincare Presence
Galderma to Buy ZO Skin Health for $1.5 Billion
The dermatology company agreed to acquire ZO Skin Health from its shareholders, including the Obagi family and funds managed by Blackstone Tactical Opportunities.
Galderma To Acquire ZO Skin Health For $1.5 Bln
(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, on Wednesday announced that it has agreed to acquire ZO Skin Health from Blackstone Inc. (BX) for an enterprise value of...
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
ZUG, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built ...
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing...
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis t...
Galderma Highlights Recent Restylane Approvals At 30-Year Mark
(RTTNews) - Galderma Group AG (GALD.SW, GDERF) announced that its Restylane injectable aesthetic product line has reached its 30th anniversary since its European launch. Restylane, which was introduce...
EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nem...
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Acad...
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland’s Leading Blue Chip Companies
ZUG, Switzerland — Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland’s leading blue chip equity benchm...
Galderma mindful of focus while eyeing product range expansion, CEO tells FuW
Galderma's CEO said the Swiss skincare firm plans to expand its product range at some point but would remain cautious not to lose its focus, speaking in an interview with Swiss newspaper Finanz und...
Galderma Reports Positive Topline Results For Restylane Volyme In Temple Hollowing Study
(RTTNews) - Galderma Group AG (GALD.SW, GDERF), a dermatology company, announced on Wednesday positive topline results from a study of Restylane Volyme for correcting moderate-to-severe temple hollowi...
Galderma's Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patie...
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin reg...
Galderma Group AG Earnings Call Transcript: Q2 2026
Record H1 2026 net sales of $3.1B, up 24.6% year-on-year, with strong double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year guidance was raised to 19%-21% net sales growth, with Nemluvio on track for $1B in sales.
Galderma Group AG Earnings release: Q2 2026
Galderma Group AG released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Galderma Group AG Quarterly report: Q2 2026
Galderma Group AG has published its Q2 2026 quarterly earnings report on July 23, 2026.
Galderma Group AG Slides: Q2 2026
Galderma Group AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report takin...
Galderma Reports Record First Half 2026 Net Sales of 3.134 Billion USD and 24.6% Year-on-Year Growth at Constant Currency, Raises Net Sales Guidance for the Full Year
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2026. Net sales reached 3.134 b...
Galderma Launches Alastin® in Japan and Key Markets Across Asia Pacific, Expanding Its Footprint in the Region
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the launch of Alastin – its premium regenerative skincare brand – across the JPAC re...
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA wit...
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the ...